Abstract:The advent of liquid biopsies has brought significant changes to the diagnosis and monitoring of non-small cell lung cancer (NSCLC), presenting both promise and challenges. Molecularly targeted drugs, capable of enhancing survival rates, are now available to around a quarter of NSCLC patients. However, to ensure their effectiveness, precision diagnosis is essential. Circulating tumor DNA (ctDNA) analysis as the most advanced liquid biopsy modality to date offers a non-invasive method for tracking genomic changes in NSCLC. The potential of ctDNA is particularly rooted in its ability to furnish comprehensive (epi-)genetic insights into the tumor, thereby aiding personalized treatment strategies. One of the key advantages of ctDNA-based liquid biopsies in NSCLC is their ability to capture tumor heterogeneity. This capability ensures a more precise depiction of the tumor's (epi-)genomic landscape compared to conventional tissue biopsies. Consequently, it facilitates the identification of (epi-)genetic alterations, enabling informed treatment decisions, disease progression monitoring, and early detection of resistance-causing mutations for timely therapeutic interventions. Here we review the current state-of-the-art in ctDNA-based liquid biopsy technologies for NSCLC, exploring their potential to revolutionize clinical practice. Key advancements in ctDNA detection methods, including PCR-based assays, next-generation sequencing (NGS), and digital PCR (dPCR), are discussed, along with their respective strengths and limitations. Additionally, the clinical utility of ctDNA analysis in guiding treatment decisions, monitoring treatment response, detecting minimal residual disease, and identifying emerging resistance mechanisms is examined. Liquid biopsy analysis bears the potential of transforming NSCLC management by enabling non-invasive monitoring of Minimal Residual Disease and providing early indicators for response to targeted treatments including immunotherapy. Furthermore, considerations regarding sample collection, processing, and data interpretation are highlighted as crucial factors influencing the reliability and reproducibility of ctDNA-based assays. Addressing these challenges will be essential for the widespread adoption of ctDNA-based liquid biopsies in routine clinical practice, ultimately paving the way toward personalized medicine and improved outcomes for patients with NSCLC.

Advances in liquid biopsy–based markers in NSCLC

Clinical application of liquid biopsy based on circulating tumor DNA in non-small cell lung cancer

Liquid biopsy on the horizon in immunotherapy of non-small cell lung cancer: current status, challenges, and perspectives

Liquid biopsy for early diagnosis of non-small cell lung carcinoma: recent research and detection technologies

Update on liquid biopsy in clinical management of non-small cell lung cancer

Blood-based Tumor Markers in Lung Cancer

Application of Circulating Tumor DNA As a Biomarker for Non-Small Cell Lung Cancer

Liquid Biopsy in Lung Cancer: Clinical Applications of Circulating Biomarkers (CTCs and ctDNA)

Liquid Biopsy in Lung Cancer: Nano-Flow Cytometry Detection of Non-Small Cell Lung Cancer in Blood

Liquid biopsy in newly diagnosed patients with locoregional (I-IIIA) non-small cell lung cancer

Liquid biopsy techniques and lung cancer: diagnosis, monitoring and evaluation

[Advances in Liquid Biopsy and Its Clinical Application in the Diagnosis and Treatment of Non-small Cell Lung Cancer].

Blood-based liquid biopsy: Insights into early detection and clinical management of lung cancer

Liquid biopsy in lung cancer: significance in diagnostics, prediction, and treatment monitoring

Overview of the Role of Liquid Biopsy in Non-small Cell Lung Cancer (NSCLC)

Emerging Non-Invasive Detection Methodologies For Lung Cancer

Diagnostic and prognostic role of liquid biopsy in non-small cell lung cancer: evaluation of circulating biomarkers

The Liquid Biopsy for Lung Cancer: State of the Art, Limitations and Future Developments

Development of new techniques and clinical applications of liquid biopsy in lung cancer management

Liquid biopsy: Circulating exosomal long noncoding RNAs in cancer

Unlocking the future of cancer diagnosis - promises and challenges of ctDNA-based liquid biopsies in non-small cell lung cancer